Praxis Precision Medicines Inc [PRAX] stock is trading at $36.21, down -5.95%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PRAX shares have gain 7.93% over the last week, with a monthly amount drifted -58.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Praxis Precision Medicines Inc [NASDAQ: PRAX] stock has seen the most recent analyst activity on March 03, 2025, when H.C. Wainwright reiterated its Buy rating and also revised its price target to $105 from $120. Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $111. On August 05, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $134 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $145 on June 24, 2024. Guggenheim initiated its recommendation with a Buy and recommended $155 as its price target on June 18, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on May 01, 2024, and assigned it a price target of $117. In a note dated September 19, 2023, Truist initiated an Buy rating and provided a target price of $10 on this stock.
Praxis Precision Medicines Inc [PRAX] stock has fluctuated between $30.01 and $91.83 over the past year. Currently, Wall Street analysts expect the stock to reach $90.75 within the next 12 months. Praxis Precision Medicines Inc [NASDAQ: PRAX] shares were valued at $36.21 at the most recent close of the market. An investor can expect a potential return of 150.62% based on the average PRAX price forecast.
Analyzing the PRAX fundamentals
Praxis Precision Medicines Inc [NASDAQ:PRAX] reported sales of 8.55M for the trailing twelve months, which represents a growth of 1349.13%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -23.4%, Pretax Profit Margin comes in at -21.37%, and Net Profit Margin reading is -21.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.5 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.63 points at the first support level, and at 33.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 38.08, and for the 2nd resistance point, it is at 39.95.
Ratios To Look Out For
For context, Praxis Precision Medicines Inc’s Current Ratio is 10.77. In addition, the Quick Ratio stands at 10.77 and the Cash Ratio stands at 5.74. Considering the valuation of this stock, the price to sales ratio is 85.39, the price to book ratio is 1.58.
Transactions by insiders
Recent insider trading involved Nemiroff Alex, General Counsel and Secretary, that happened on Nov 14 ’24 when 8239.0 shares were sold. Principal Accounting Officer, Mastrocola Lauren completed a deal on Nov 14 ’24 to sell 5188.0 shares. Meanwhile, Officer Mastrocola Lauren bought 5189.0 shares on Nov 14 ’24.
